fashion -WSS

fashion

author：knowledge 2025-08-26 23:44:13 - browse：4

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Male and female sex labels in research insufficient, scientists say

WSS

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Vertex non

New Ultima Genomics DNA sequencer can read genome for $100

How to save health care price transparency rules

First U.S. drug developed to treat liver disease MASH is approved

Wikipedia

fashion

focus

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: CAR

Anesthesiologist group: stop taking Ozempic before surgery

As AI in medicine takes off, can 'human in the loop' prevent harm?

Sports medicine is finally prioritizing gender equality

Cybersecurity threat forces Lurie Children's to take systems offline

Supreme Court strikes down use of affirmative action

Medicare coverage of Wegovy, once blocked, now looks possible

How one medical school became remarkably diverse

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

knowledge

How to save health care price transparency rules

EPA limits use of carcinogenic gas for sterilizing medical devices

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Amid AI frenzy, a top HHS official's quest to create safeguards

How to save health care price transparency rules

knowledge

knowledge

hotspot

knowledge